Volume 19, Issue 7, Pages (July 2017)

Slides:



Advertisements
Similar presentations
Cell Physiol Biochem 2013;32: DOI: /
Advertisements

Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model  Jiang Liu, MD, Penny C.
Volume 9, Issue 2, Pages (August 2017)
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Volume 18, Issue 12, Pages (December 2016)
Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis  Katsunari Makino,
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
Volume 16, Issue 3, Pages e4 (March 2014)
CCN family 2/connective tissue growth factor (CCN2/CTGF) stimulates proliferation and differentiation of auricular chondrocytes  T. Fujisawa, Ph.D., D.D.S.,
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
Volume 20, Issue 4, Pages e4 (April 2017)
A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling
The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma  Christine M. Heske, Choh Yeung, Arnulfo.
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT  Zhen-Yu He, San-Gang Wu, Fang Peng,
RET Mutation and Expression in Small-Cell Lung Cancer
A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling
Volume 118, Issue 4, Pages (April 2000)
Volume 134, Issue 1, Pages (January 2008)
Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M
Volume 8, Issue 6, Pages (September 2014)
Volume 19, Issue 8, Pages (August 2017)
Volume 7, Issue 4, Pages (October 2016)
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Volume 23, Issue 6, Pages (June 2013)
Volume 26, Issue 2, Pages (August 2014)
Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer  Tadaaki Yamada, MD, PhD, Shinji Takeuchi,
NRP2 represses IGF-IR expression and signaling.
Volume 138, Issue 5, Pages e2 (May 2010)
Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model  Jiang Liu, MD, Penny C.
Volume 19, Issue 2, Pages (February 2011)
Volume 23, Issue 1, Pages (January 2013)
Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed  Mugdha.
Activation of the Innate Signaling Molecule MAVS by Bunyavirus Infection Upregulates the Adaptor Protein SARM1, Leading to Neuronal Death  Piyali Mukherjee,
Volume 29, Issue 4, Pages (April 2016)
Aromatase Inhibitor Exemestane has Antiproliferative Effects on Human Mesothelioma Cells  Daniela Stoppoloni, BSc, Luisa Salvatori, BSc, Annamaria Biroccio,
Volume 133, Issue 4, Pages (October 2007)
Volume 11, Issue 2, Pages (February 2007)
Volume 14, Issue 7, Pages (July 2007)
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation  Yosuke.
Volume 9, Issue 6, Pages (December 2017)
Volume 9, Issue 2, Pages (August 2017)
Volume 16, Issue 11, Pages (September 2016)
Volume 10, Issue 1, Pages (July 2006)
Stable and Potent Selenomab-Drug Conjugates
Molecular Therapy - Nucleic Acids
Volume 39, Issue 3, Pages (September 2013)
Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation  Yosuke.
Volume 68, Issue 2, Pages (August 2005)
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
Volume 38, Issue 1, Pages (April 2010)
Multiple Functions of the 37/67-kd Laminin Receptor Make It a Suitable Target for Novel Cancer Gene Therapy  Jonathan Scheiman, Jen-Chieh Tseng, Yun Zheng,
Volume 20, Issue 4, Pages (October 2011)
Marta Vilalta, Marjan Rafat, Amato J. Giaccia, Edward E. Graves 
Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells  Jeffrey A. Brockman, Rajnish A. Gupta, Raymond.
Volume 16, Issue 12, Pages (June 2006)
Volume 19, Issue 1, Pages (April 2017)
PPARδ Is a Type 1 IFN Target Gene and Inhibits Apoptosis in T Cells
Volume 15, Issue 2, Pages (April 2016)
In Vivo Tracking of Mesechymal Stem Cells Using Fluorescent Nanoparticles in an Osteochondral Repair Model  Jong Min Lee, Byung-Soo Kim, Haeshin Lee,
Volume 12, Issue 4, Pages (July 2015)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 18, Issue 3, Pages (March 2010)
Volume 167, Issue 2, Pages e9 (October 2016)
Volume 39, Issue 3, Pages (August 2010)
Volume 11, Issue 4, Pages (April 2015)
John M. Lamar, Vandana Iyer, C. Michael DiPersio 
by Emilie Clement, Hiroyuki Inuzuka, Naoe T
Molecular Therapy - Nucleic Acids
Presentation transcript:

Volume 19, Issue 7, Pages 564-573 (July 2017) Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)  Madhura Joglekar-Javadekar, Steven Van Laere, Michael Bourne, Manal Moalwi, Pascal Finetti, Peter B. Vermeulen, Daniel Birnbaum, Luc Y. Dirix, Naoto Ueno, Monique Carter, Justin Rains, Abhijit Ramachandran, Francois Bertucci, Kenneth L. van Golen  Neoplasia  Volume 19, Issue 7, Pages 564-573 (July 2017) DOI: 10.1016/j.neo.2017.03.002 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Generation of a robust predictive model for PDGFRA activation in GIST and application to breast cancer samples. (A) Classification of 29 GIST samples from the learning set (Ostrowki's set). (Left) Box-plot showing the distribution of posterior probabilities, according to our predictive model, of presence of PDGFRA mutation in samples without (“WT”) and with (“mut.”) PDGFRA mutation. (Right) Cross-table between the observed PDGFRA status (“mut.” versus “WT”) and the predicted PDGFRA activation status according to our model. (B) Similar to A but applied to the validation series of 213 GIST samples. (C) Cross-table between the predicted “PDGFRA-activated” status and the clinical phenotype (IBC versus non-IBC) of 137 IBC samples and 252 non-IBC samples collected through the IBC International Consortium gene expression data set. (D) Kaplan-Meier MFS in patients with IBC according to the predicted PDGFRA activation status: “activated” (black curve) versus “not activated” (gray curve). The respective 5-year MFSs were 52% and 72%. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Expression of PDGFRA and PDGF ligands in IBC cells. (A) Representative immunoblot for total and tyrosine phosphorylated PDGFRA in SUM149, KPL-4, and MDA-MB-231 cells grown in monolayer with and without 10% serum or 10-ng/ml exogenous PDGF-BB stimulation for 10 minutes. GAPDH was used as a loading control. (B) Quantitation of PDGFRA immunoblots. Densitometry was performed on nonsaturated immunoblots using ImageJ analysis. A ratio of pPDGFRA to total PDGFRA is reported. (C) Representative RT-PCR for PDGF ligands expressed by the SUM149 IBC cell line. Cells were grown under standard conditions. Control is β-actin. (D) Results of an ELISA assay for PDGF-AA and PDGF-BB produced by breast cancer cell lines and compared with HMECs. Cells were grown to 75% confluence; medium was changed and assayed 48hours later. IBC cells were compared to the non-IBC MDA-MB-231 cells. Error bars represent SD, *P≤.001. All experiments were performed in at least triplicate. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Pharmacologic inhibition of PDGFRA. (A) Dose response of imatinib and crenolanib treatment on SUM149 and KPL-4 cells grown in monolayer. Cells were treated with a dose range from 0 to 200 μM imatinib or 0 to 20 μM crenolanib for 48hours and assessed by MTT. Effect on cell survival was compared in parallel with vehicle controls. Error bars represent SD, *P≤.001. ND=not done. (B) Cell cycle analysis by propidium iodide staining of SUM149 cells treated with 2 μM or 5 μM crenolanib for 12 hours. Untreated and DMSO-treated cells were used as controls. FACS analysis data were processed using CellQuest and Mod-Fit software. The bar graph is quantification of the data showing the percentage of cells in G1, G2/M, and S phases, Error bars represent SD,*P≤.05. (C) Dose response of imatinib and crenolanib treatment on SUM149 and KPL-4 cells grown as three-dimensional emboli. Cells were treated with a dose range from 0 to 200 μM imatinib or 0 to 5 μM crenolanib for 48 hours; emboli were harvested and assessed by direct counting, which was compared in parallel with vehicle controls. Error bars represent SD, *P≤.001. Each experiment was performed in at least triplicate. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Crenolanib treatment of an orthotopic IBC tumor. Orthotopic SUM149 tumors were established in female athymic nude mice and grown to ~200 mm3 in size. Mice were randomized to control and treatment groups, and Alzet micro-osmotic pumps were implanted subcutaneously, represented as day 1. Micropumps contained either crenolanib or DMSO vehicle, and treatment lasted for 10 days. Tumors were measured daily. Error bars represent SD, *P≤.0001. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 1 Box-plot of mRNA expression of PDGFs according to the predicted PDGFRA activation status in breast cancers. (A) mRNA expression of PDGF-A in all 389 breast cancer samples according to the predicted PDGFRA activation status (“activated” versus “not activated”). (B-D) Similar to A, but for PDGF-B, PDGF-C, and PDGF-D, respectively. The P values (Student's t test) are .37, 1.3E-07, 2.6E-08, and .15, respectively. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 2 Pharmacologic inhibition of PDGFRA in MDA-MB-231 cells. Dose response of imatinib and crenolanib treatment on SUM149 and KPL-4 cells grown in monolayer. Cells were treated with a dose range from 0 to 200 μM imatinib or 0 to 20 μM crenolanib for 48hours and assessed by MTT. Effect on cell survival was compared in parallel with vehicle controls. Error bars represent SD, *P ≤ .001. ND=not done. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 3 Crenolanib treatment of an orthotopic IBC tumor. Orthotopic SUM149 tumors were established in female athymic nude mice and grown to ~200 mm3 in size. Mice were randomized to control and treatment groups, and Alzet micro-osmotic pumps were implanted subcutaneously, represented as day 1. Micropumps contained either crenolanib or DMSO vehicle, and treatment lasted 10 days (arrow). Mice were kept for an additional 4 days, and tumors were measured daily. Neoplasia 2017 19, 564-573DOI: (10.1016/j.neo.2017.03.002) Copyright © 2017 The Authors Terms and Conditions